Enanta Pharmaceuticals宣布在欧洲肝脏研究协会（EASL）2020数字国

StephenW

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2020
August 20, 2020 07:00 AM Eastern Daylight Time

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that clinical data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) have been accepted for presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress 2020 being held August 27-29, 2020.

    “EDP-305, A Non-Bile Acid Farnesoid X Receptor (FXR) Agonist, Showed Statistically Significant Improvements in Liver Biochemistry and Hepatic Steatosis in the Phase 2a ARGON-1 Study”

Clinical data will include an oral presentation of the Phase 2a ARGON-1 study of EDP-305, Enanta’s Farnesoid X receptor (FXR) agonist for the treatment of NASH, as well as a poster on new Phase 1 data of EDP-514, Enanta’s core inhibitor for HBV. Preclinical data on EDP-297, Enanta’s follow-on FXR agonist for NASH, will also be highlighted in two poster presentations.

The full scientific program for The Digital International Liver Congress 2020, as well as the abstracts, can be found at https://ilc-congress.eu/programme-digital-ilc-2020/. Further details will be available at the time of these presentations.

Oral Presentation:
August 28, 2020, 12:15 - 12:30 CEST
AS078: “EDP-305, A Non-Bile Acid Farnesoid X Receptor (FXR) Agonist, Showed Statistically Significant Improvements in Liver Biochemistry and Hepatic Steatosis in the Phase 2a ARGON-1 Study”
Location: Channel 3
Presenter: Vlad Ratziu, M.D., Ph.D., France

Poster Presentations:
August 28, 2020, 09:30 - 19:30 CEST
FRI109: “EDP-297, A Novel and Potent FXR Agonist, Exhibits Robust Anti-Fibrotic Effects with Significant Liver Function Improvement in a Rat Model of Non-Alcoholic Steatohepatitis”
Presenter: Mozhdeh Sojoodi, Ph.D., United States

August 29, 2020, 09:30 - 19:30 CEST
SAT042: “A Novel FXR Agonist EDP-297 Exerts Anti-Inflammatory and Hepatoprotective Effects in Human Liver 3D Microtissues and in Rodent Models of Liver Injury and NASH”
Presenter: Mary Chau, Ph.D., United States

August 29, 2020, 09:30 - 19:30 CEST
SAT440: “EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects”
Presenter: Kajal Larson, Ph.D., United States

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

Contacts

Investors
Jennifer Viera
617-744-3848
[email protected]

StephenW

Enanta Pharmaceuticals宣布在欧洲肝脏研究协会（EASL）2020数字国际肝脏大会™上进行数据演示
2020年8月20日，东部夏令时间上午07:00

马萨诸塞州沃特敦-（BUSINESS WIRE）-（美国商业资讯）-致力于开发用于病毒感染和肝病的小分子药物的临床阶段生物技术公司Enanta Pharmaceuticals，Inc.（NASDAQ：ENTA）今天宣布，Enanta的全部临床数据的非酒精性脂肪性肝炎（NASH）和乙型肝炎病毒（HBV）拥有的开发计划已在2020年8月27日至29日举行的2020年欧洲肝脏研究协会（EASL）数字国际肝脏大会上进行介绍。

    “ EDP-305，一种非胆汁酸法呢素X受体（FXR）激动剂，在2a ARGON-1期研究中显示出肝脏生物化学和肝脂肪变性的统计学显着改善”

临床数据将包括对Enanta用于治疗NASH的Farantaoid X受体（FXR）激动剂EDP-305的2a ARGON-1期研究的口头陈述，以及Enanta的EDP-514新的1期数据的海报。 HBV核心抑制剂。 Enanta继NASH上的FXR激动剂EDP-297的临床前数据也将在两个海报展示中重点介绍。

可以在https://ilc-congress.eu/programme-digital-ilc-2020/上找到2020年数字国际肝脏大会的完整科学计划以及摘要。在这些演示时，将提供更多详细信息。

口头表达：
2020年8月28日，美国东部时间12:15-12:30
AS078：“ EDP-305，一种非胆汁酸法呢素X受体（FXR）激动剂，在2a ARGON-1期研究中显示出肝脏生物化学和肝脂肪变性的统计学显着改善”
位置：第3频道
演讲人：法国医学博士Vlad Ratziu

海报展示：
2020年8月28日，美国东部时间上午9:30-19:30
FRI109：“ EDP-297，一种新型有效的FXR激动剂，在非酒精性脂肪性肝炎大鼠模型中表现出强大的抗纤维化作用，并显着改善了肝功能”
演讲者：Mozhdeh Sojoodi博士，美国

2020年8月29日，美国中部标准时间（CEST）
SAT042：“新型FXR激动剂EDP-297在人类肝脏3D微组织以及啮齿动物肝损伤和NASH模型中具有抗炎和保肝作用”
演讲人：周美琪博士，美国

东部时间2020年8月29日，09：30-19:30
SAT440：“ EDP-514，新型泛型II类乙型肝炎病毒核心抑制剂：健康成人受试者的1期研究最终结果”
演讲人：Kajal Larson博士，美国

关于Enanta

Enanta正在使用其强大的，化学驱动的方法和药物发现能力来成为发现和开发用于治疗病毒感染和肝病的小分子药物的领导者。 Enanta的研究和开发成果为以下疾病目标提供了临床候选药物：呼吸道合胞病毒（RSV），非酒精性脂肪性肝炎（NASH）和乙型肝炎病毒（HBV）。 Enanta还正在进行人类偏肺病毒（hMPV）和SARS-CoV-2（COVID-19）的研究。

Enanta的研发活动由与AbbVie合作开发的丙型肝炎病毒（HCV）产品的特许权使用费资助。由Enanta公司发现的蛋白酶抑制剂Glecaprevir被AbbVie在许多国家出售，作为其领先的慢性HCV感染治疗方法的一部分，商品名为MAVYRET®（美国）和MAVIRET®（ex-U.S。）（glecaprevir / pibrentasvir）。请访问www.enanta.com了解更多信息。

联络人

投资人
珍妮佛·维埃拉（Jennifer Viera）
617-744-3848
[email protected]